

May 2013 DUR BOARD PDL MEETING MINUTES

Date: May 29, 2013

Members Present: Sather, Brown, Burton, Crichton, Caldwell, Putsch, Fitzgerald, Anglim, Harrison

Others Present: Dan Peterson, Dave Campana, Katie Hawkins (Medicaid), Kathy Novak (Magellan), Woodmansey and Barnhill (Drug PA/CM unit), and various members of the public and representatives of drug manufacturers.

Lisa called the meeting to order.

Public Comment Period: No one offered public comment at this time.

The March DUR Board meeting minutes were reviewed and approved.

Department Update:

The Department proposed regulations that provide for paying pharmacists for vaccine administration is moving through the system and will be implemented July 1, 2013. The revised regulation to pay the higher preferred brand, generic and other generic drugs dispensing fee at \$ 6.52 is also moving through the process and will be implemented on July 1, 2013. The \$ 6.52 is payable if a pharmacy's costs of dispensing support this level and the pharmacy completed their yearly cost of dispensing survey. In August the Department will conduct the annual drug actual acquisition cost survey. This survey is completed to assess if the State Maximum Allowable Cost (SMAC) list is paying for drugs at the correct rate and is not under paying cost of generics that are included in the SMAC list.

PDL Review:

The Department reviewed the following classes as **NEW** information is known to exist. The Board made the following recommendations to the Department:

- ACNE AGENTS –
 - *BENZOYL PEROXIDE COMBOS*- Class Effect
 - *BENZOYL PEROXIDE AGENTS*- Class Effect
 - *CLINDAMYCIN AGENTS*- Class Effect
 - *SODIUM SULFACETAMIDE AGENTS*- Class Effect
 - *AZELAIC ACID*-May add
 - *DAPSONE TOPICAL*-May add
 - *TOPICAL RETINOIDS & Combos*- Class Effect- Grandfather (Dept declined 5/2010)
 - *ERYTHROMYCIN TOPICAL*- Class Effect
- ANTIBIOTICS, GI- New Category. No Grandfather.
 - Must have metronidazole and vancomycin- May add others.
- ANTIBIOTICS, INHALED-New Category
 - Therapeutic alternatives-Grandfather
- ANTIBIOTICS, VAGINAL-New Category. No Grandfather.
 - Therapeutic alternatives
- ANTIFUNGALS, ORAL
Must have terbinafine and fluconazole; Must have 1 of clotrimazole or nystatin; May add itraconazole and griseofulvin for Onychomycosis.
- ANTIPSORIATICS, TOPICAL-New Category
 - Class effect; Must have one topical formulation and a scalp formulation. Continue PA criteria. Grandfather by chemical entity.
- ANTIVIRALS, ORAL- Category expansion. No Grandfather.
 - *HSV ANTIVIRALS*- Class Effects
 - *INFLUENZA ANTIVIRALS*- Must have CDC recommended agents which are oseltamivir (Tamiflu®) and zanamivir (Relenza®).
- BLADDER RELAXANTS – Must have 1 long acting agent (either by half-life or dosage form)

- COPD AGENTS – Grandfather
Must have ipratropium in some form; May add others. Therapeutic Duplication criteria for tiotropium (Spiriva®), aclidinium (Tudorza®), and ipratropium.
- CYTOKINES & CAM ANTAGONISTS & RELATED-Category name change
 - Therapeutic alternatives; Do not add Anakinra (Kineret®), add PA Criteria on Xeljanz, Grandfather
- EPINEPHRINE, SELF-INJECTED-New Category- No Grandfather.
 - Class Effect
- ORAL GLUCOCORTICOIDS-New Category. No Grandfather.
 - *SHORT ACTING*; *cortisone, hydrocortisone* - Therapeutic alternatives
 - *INTERMEDIATE ACTING*; *methylprednisolone, prednisone, and prednisolone*- Therapeutic alternatives, must include a dosepack.
 - *LONG ACTING*; *betamethasone, dexamethasone* - Therapeutic alternatives
 - *BUDESONIDE*- Must have 1 budesonide.
- HEPATITIS C AGENTS –Grandfather. Add PA criteria for ribavirins and pegylated interferon. Must be prescribed by appropriate specialist or have a specialist consult.
 - *RIBIVIRINS*- Class Effect
 - *PEGYLATED INTERFERON*- Class Effect
 - *PROTEASE INHIBITORS*- Must have telaprevir (Incivek®), may add boceprevir (Victrelis®). Continue PA requirements.
- HYPOGLYCEMICS, METFORMINS -New category. Grandfather.
 - Must have metformin IR; May add metformin ER and/or combos.
- IMMUNOSUPPRESSANTS –Full Review- Grandfather
 - Must have all chemical entities; May add Zortress®
- INTRANASAL RHINITIS AGENTS –No Grandfather
 - *NASAL CORTICOSTEROIDS*- Class Effect
 - *NASAL ANTIHISTAMINES & OTHERS*- Class Effect; Must have an ipratropium product.
- MACROLIDES & KETOLIDES- Class Effect; Must have azithromycin, clarithromycin, erythromycin.
- SMOKING CESSATION- New Category. Continue PA requirements.
 - *NICOTINE REPLACEMENT* – In addition to OTC nicotine patches, recommend an OTC nicotine lozenge or gum be added with limits.
 - *NON-NICOTINE* – Must have Chantix (continue current PA warnings to prescribers).
- TETRACYCLINES – New Category.
 - Must have doxycycline. May add others.
- TOPICAL STEROIDS- New Category
 - *LOW POTENCY*- Class Effect; Must have 1 cream and 1 ointment, may add other forms
 - *MEDIUM POTENCY*- Class Effect; Must have 1 cream and 1 ointment, may add other forms
 - *HIGH POTENCY*- Class Effect; Must have 1 cream and 1 ointment, may add other forms
 - *VERY HIGH POTENCY*- Class Effect; Must have 1 cream and 1 ointment, may add other forms

(The following classes were not reviewed because no **NEW** information was submitted)
The Department proposed no changes to the Formulary Committee's previous clinical recommendations. The Board recommendations are as follows:

- MINIMALLY SEDATING ANTIHISTAMINES and DECONGESTANT COMBOs
Category name change

- Must have 1 single ingredient agent.
- ANTIVIRALS, TOPICAL - Class Effect
- BPH AGENTS-
 - *ALPHA BLOCKERS*- Class Effect
 - *ANDROGEN HORMONE INHIBITORS AND COMBOS*- Class Effect
 - *PDE5 for BPH*- Tadalafil (Cialis®) will be non-preferred with PA criteria
- CEPHALOSPORINS & Related Antibiotics -
 - *2nd GENERATION*-Class effect
 - *3RD GENERATION*- Class effect
- FLUOROQUINOLONES, ORAL –
 - *2nd Gen*- Must have ciprofloxacin; Others are class effect, may add
- INHALED GLUCOCORTICOIDS & COMBOS – Class effect
- LABA INHALERS & NEBS – Class effect. Must have 1 inhaler form.
- LEUKOTRIENE MODIFIERS – Must have montelukast (Singulair®); May add zafirlukast
- SABA INHALERS & NEBS – Class effect. Grandfathered (by chemical entity, not brand)
- TOPICAL ANTIBIOTICS – Must have a mupirocin product; May have retapamulin (Altabax®)
- TOPICAL IMMUNOMODULATORS – Class effect. Must have one. PA requirements are in place.

There were no green classes for this meeting

The next meeting will be Wednesday June 26, 2013 at The Holiday Inn Downtown.
The meeting was adjourned at 4:50.